CSL and Arcturus Therapeutics achieve a breakthrough as KOSTAIVE becomes the first self-amplifying mRNA COVID-19 vaccine approved by the European Commission for adults 18 and older.
Arcturus Therapeutics anticipates Phase 2 LunairCF study data for ARCT-032 in cystic fibrosis patients unresponsive to existing modulators, expected in the first half of 2025.